Elucidation of the interaction between crosstalk between ER and HER2 and drug resistance mechanism in breast cancer

2016 Fiscal Year Final Research Report

• Project/Area Number: 26861055
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: General surgery
• Research Institution: Juntendo University
• Principal Investigator: TOKUDA Emi 順天堂大学, 医学部, 非常勤助教 (70621960)
• Research Collaborator: HORIMOTO yoshiya 順天堂大学, 医学部, 准教授 (40424246) ; ARAKAWA Atsushi 順天堂大学, 医学部, 准教授 (70245695)
• Project Period (FY): 2014-04-01 – 2017-03-31
• Keywords: ER陽性HER2陽性乳癌 / 薬剤耐性 / クロストーク

Outline of Final Research Achievements

We investigated the mechanism of drug resistance on triple-positive breast cancer in which estrogen receptor (ER) and HER2 protein are highly expressed, which are survival and proliferative pathway.
Triple-positive breast cancer cell line: BT474 and BT474-R cells that had established long-term administration of trastuzumab that blocks HER2 signal to BT474 were used to analyze changes of some proteins in signal pathway and change of gene expression. By acquiring resistance to trastuzumab, protein expression of the ER signal was high expressed, and a group of genes producing estrogen were activated.

Free Research Field

医学